Cargando…

Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts

We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Sánchez-Maldonado, Jose Manuel, Cáliz, Rafael, López-Nevot, Miguel Ángel, Cabrera-Serrano, Antonio José, Moñiz-Díez, Ana, Canhão, Helena, Ter Horst, Rob, Quartuccio, Luca, Sorensen, Signe B., Glintborg, Bente, Hetland, Merete L., Filipescu, Ileana, Pérez-Pampin, Eva, Conesa-Zamora, Pablo, Swierkot, Jerzy, den Broeder, Alfons A., De Vita, Salvatore, Petersen, Eva Rabing Brix, Li, Yang, Ferrer, Miguel A., Escudero, Alejandro, Netea, Mihai G., Coenen, Marieke J. H., Andersen, Vibeke, Fonseca, João E., Jurado, Manuel, Bogunia-Kubik, Katarzyna, Collantes, Eduardo, Sainz, Juan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579100/
https://www.ncbi.nlm.nih.gov/pubmed/34777329
http://dx.doi.org/10.3389/fimmu.2021.672255
_version_ 1784596372329070592
author Sánchez-Maldonado, Jose Manuel
Cáliz, Rafael
López-Nevot, Miguel Ángel
Cabrera-Serrano, Antonio José
Moñiz-Díez, Ana
Canhão, Helena
Ter Horst, Rob
Quartuccio, Luca
Sorensen, Signe B.
Glintborg, Bente
Hetland, Merete L.
Filipescu, Ileana
Pérez-Pampin, Eva
Conesa-Zamora, Pablo
Swierkot, Jerzy
den Broeder, Alfons A.
De Vita, Salvatore
Petersen, Eva Rabing Brix
Li, Yang
Ferrer, Miguel A.
Escudero, Alejandro
Netea, Mihai G.
Coenen, Marieke J. H.
Andersen, Vibeke
Fonseca, João E.
Jurado, Manuel
Bogunia-Kubik, Katarzyna
Collantes, Eduardo
Sainz, Juan
author_facet Sánchez-Maldonado, Jose Manuel
Cáliz, Rafael
López-Nevot, Miguel Ángel
Cabrera-Serrano, Antonio José
Moñiz-Díez, Ana
Canhão, Helena
Ter Horst, Rob
Quartuccio, Luca
Sorensen, Signe B.
Glintborg, Bente
Hetland, Merete L.
Filipescu, Ileana
Pérez-Pampin, Eva
Conesa-Zamora, Pablo
Swierkot, Jerzy
den Broeder, Alfons A.
De Vita, Salvatore
Petersen, Eva Rabing Brix
Li, Yang
Ferrer, Miguel A.
Escudero, Alejandro
Netea, Mihai G.
Coenen, Marieke J. H.
Andersen, Vibeke
Fonseca, João E.
Jurado, Manuel
Bogunia-Kubik, Katarzyna
Collantes, Eduardo
Sainz, Juan
author_sort Sánchez-Maldonado, Jose Manuel
collection PubMed
description We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (ΔDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549 (rs7767069) SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (per-allele OR(Meta)=0.83, P (Meta)=0.000077; P (Het)=0.61). In addition, we found that each copy of the LRRC55 (rs717117G) allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele OR(Meta)=0.67, P=0.00058; P (Het)=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele OR(Meta)=1.38, P=0.10; P (Het)=0.45; P (Interaction)=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the meta-analysis also showed overall and RF-specific associations for the MAFB (rs6071980) and CNTN5 (rs1813443) SNPs with decreased changes in DAS28 (per-allele OR(Meta_rs6071980) = 0.85, P=0.0059; P (Het)=0.63 and OR(Meta_rs1813443_RF+)=0.81, P=0.0059; P (Het)=0.69 and OR(Meta_rs1813443_RF-)=1.00, P=0.99; P (Het)=0.12; P (Interaction)=0.032). Mechanistically, we found that subjects carrying the LINC02549 (rs7767069T) allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549 (rs7767069T/T) genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55 (rs717117G) allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated.
format Online
Article
Text
id pubmed-8579100
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85791002021-11-11 Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts Sánchez-Maldonado, Jose Manuel Cáliz, Rafael López-Nevot, Miguel Ángel Cabrera-Serrano, Antonio José Moñiz-Díez, Ana Canhão, Helena Ter Horst, Rob Quartuccio, Luca Sorensen, Signe B. Glintborg, Bente Hetland, Merete L. Filipescu, Ileana Pérez-Pampin, Eva Conesa-Zamora, Pablo Swierkot, Jerzy den Broeder, Alfons A. De Vita, Salvatore Petersen, Eva Rabing Brix Li, Yang Ferrer, Miguel A. Escudero, Alejandro Netea, Mihai G. Coenen, Marieke J. H. Andersen, Vibeke Fonseca, João E. Jurado, Manuel Bogunia-Kubik, Katarzyna Collantes, Eduardo Sainz, Juan Front Immunol Immunology We aimed to validate the association of 28 GWAS-identified genetic variants for response to TNF inhibitors (TNFi) in a discovery cohort of 1361 rheumatoid arthritis (RA) patients monitored in routine care and ascertained through the REPAIR consortium and DANBIO registry. We genotyped selected markers and evaluated their association with response to TNFi after 6 months of treatment according to the change in disease activity score 28 (ΔDAS28). Next, we confirmed the most interesting results through meta-analysis of our data with those from the DREAM cohort that included 706 RA patients treated with TNFi. The meta-analysis of the discovery cohort and DREAM registry including 2067 RA patients revealed an overall association of the LINC02549 (rs7767069) SNP with a lower improvement in DAS28 that remained significant after correction for multiple testing (per-allele OR(Meta)=0.83, P (Meta)=0.000077; P (Het)=0.61). In addition, we found that each copy of the LRRC55 (rs717117G) allele was significantly associated with lower improvement in DAS28 in rheumatoid factor (RF)-positive patients (per-allele OR(Meta)=0.67, P=0.00058; P (Het)=0.06) whereas an opposite but not significant effect was detected in RF-negative subjects (per-allele OR(Meta)=1.38, P=0.10; P (Het)=0.45; P (Interaction)=0.00028). Interestingly, although the identified associations did not survive multiple testing correction, the meta-analysis also showed overall and RF-specific associations for the MAFB (rs6071980) and CNTN5 (rs1813443) SNPs with decreased changes in DAS28 (per-allele OR(Meta_rs6071980) = 0.85, P=0.0059; P (Het)=0.63 and OR(Meta_rs1813443_RF+)=0.81, P=0.0059; P (Het)=0.69 and OR(Meta_rs1813443_RF-)=1.00, P=0.99; P (Het)=0.12; P (Interaction)=0.032). Mechanistically, we found that subjects carrying the LINC02549 (rs7767069T) allele had significantly increased numbers of CD45RO+CD45RA+ T cells (P=0.000025) whereas carriers of the LINC02549 (rs7767069T/T) genotype showed significantly increased levels of soluble scavengers CD5 and CD6 in serum (P=0.00037 and P=0.00041). In addition, carriers of the LRRC55 (rs717117G) allele showed decreased production of IL6 after stimulation of PBMCs with B burgdorferi and E coli bacteria (P=0.00046 and P=0.00044), which suggested a reduced IL6-mediated anti-inflammatory effect of this marker to worsen the response to TNFi. In conclusion, this study confirmed the influence of the LINC02549 and LRRC55 loci to determine the response to TNFi in RA patients and suggested a weak effect of the MAFB and CNTN5 loci that need to be further investigated. Frontiers Media S.A. 2021-10-27 /pmc/articles/PMC8579100/ /pubmed/34777329 http://dx.doi.org/10.3389/fimmu.2021.672255 Text en Copyright © 2021 Sánchez-Maldonado, Cáliz, López-Nevot, Cabrera-Serrano, Moñiz-Díez, Canhão, Ter Horst, Quartuccio, Sorensen, Glintborg, Hetland, Filipescu, Pérez-Pampin, Conesa-Zamora, Swierkot, den Broeder, De Vita, Petersen, Li, Ferrer, Escudero, Netea, Coenen, Andersen, Fonseca, Jurado, Bogunia-Kubik, Collantes and Sainz https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Immunology
Sánchez-Maldonado, Jose Manuel
Cáliz, Rafael
López-Nevot, Miguel Ángel
Cabrera-Serrano, Antonio José
Moñiz-Díez, Ana
Canhão, Helena
Ter Horst, Rob
Quartuccio, Luca
Sorensen, Signe B.
Glintborg, Bente
Hetland, Merete L.
Filipescu, Ileana
Pérez-Pampin, Eva
Conesa-Zamora, Pablo
Swierkot, Jerzy
den Broeder, Alfons A.
De Vita, Salvatore
Petersen, Eva Rabing Brix
Li, Yang
Ferrer, Miguel A.
Escudero, Alejandro
Netea, Mihai G.
Coenen, Marieke J. H.
Andersen, Vibeke
Fonseca, João E.
Jurado, Manuel
Bogunia-Kubik, Katarzyna
Collantes, Eduardo
Sainz, Juan
Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title_full Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title_fullStr Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title_full_unstemmed Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title_short Validation of GWAS-Identified Variants for Anti-TNF Drug Response in Rheumatoid Arthritis: A Meta-Analysis of Two Large Cohorts
title_sort validation of gwas-identified variants for anti-tnf drug response in rheumatoid arthritis: a meta-analysis of two large cohorts
topic Immunology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8579100/
https://www.ncbi.nlm.nih.gov/pubmed/34777329
http://dx.doi.org/10.3389/fimmu.2021.672255
work_keys_str_mv AT sanchezmaldonadojosemanuel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT calizrafael validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT lopeznevotmiguelangel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT cabreraserranoantoniojose validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT monizdiezana validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT canhaohelena validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT terhorstrob validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT quartuccioluca validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT sorensensigneb validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT glintborgbente validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT hetlandmeretel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT filipescuileana validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT perezpampineva validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT conesazamorapablo validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT swierkotjerzy validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT denbroederalfonsa validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT devitasalvatore validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT petersenevarabingbrix validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT liyang validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT ferrermiguela validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT escuderoalejandro validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT neteamihaig validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT coenenmariekejh validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT andersenvibeke validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT fonsecajoaoe validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT juradomanuel validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT boguniakubikkatarzyna validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT collanteseduardo validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts
AT sainzjuan validationofgwasidentifiedvariantsforantitnfdrugresponseinrheumatoidarthritisametaanalysisoftwolargecohorts